EpistemisPosological guidelines, limits and organic adjustment
This section summarizes and tabulates the clinical administration guidelines for the main micronutrients, detailing the reference intakes, maximum tolerable limits and the safety profile in pregnancy.
Mechanism
| Micronutrient | Recommended Daily Allowance (RDA) | Maximum Tolerable Limit (UL) | Adjustment in Renal / Liver Failure | Pregnancy Category (FDA) |
|---|---|---|---|---|
| Vitamin A | 700 - 900 µg RAE/day | 3000 µg RAE/day | No changes in renal failure. Reduce dose in decompensated cirrhosis due to low RBP synthesis. | Category X (Acid Forms) / Category A in physiological doses |
| Vitamin D3 | 600 - 800 IU/day | 4000 IU/day | In severe end-stage renal failure (eGFR < 30 mL/min), replace cholecalciferol with active Calcitriol. | Category C in high doses / Category A in RDA |
| Vitamin E | 15 mg/day (≈ 22.4 IU) | 1000 mg/day (≈ 1500 IU) | No adjustment required. Monitor closely if coadministered with warfarin. | Category A in RDA doses |
| Vitamin K1 | 90 - 120 µg/day | Not determined | No adjustment required. Avoid prolonged use in patients anticoagulated with vitamin K antagonists. | Category C in therapeutic doses / Category A in RDA |
| Vitamin B1 | 1.1 - 1.2 mg/day | Not determined | No adjustment required. In Beriberi replacement therapy, dose parenterally. | Category A in RDA doses |
| Vitamin B3 (Niacin) | 14 - 16 mg/day | 35 mg/day (as a supplement) | Monitor transaminases if lipid-lowering pharmacological doses are used. | Category C in megadoses / Category A in RDA |
| Vitamin B6 | 1.3 - 1.7 mg/day | 100 mg/day | No adjustment required. The use of megadoses is associated with irreversible peripheral neuropathy. | Category A in RDA doses |
| Vitamin B9 (Folic) | 400 µg/day | 1000 µg/day | No adjustment required. Useful to counteract the adverse effects of methotrexate. | Category A |
| Vitamin B12 | 2.4 µg/day | Not determined | No adjustment required. The intramuscular parenteral route avoids the gastric barrier completely. | Category A |
| Vitamin C | 75 - 90 mg/day | 2000 mg/day | Avoid megadoses in recurrent calcium oxalate nephrolithiasis. | Category A in RDA doses |
| Elemental Iron | 8 - 18 mg/day | 45 mg/day | No adjustment required. Intestinal absorption decreases in the face of systemic inflammation. | Category A in physiological doses |
| Magnesium | 310 - 420 mg/day | 350 mg/day (supplements) | Contraindicated or under strict adjustment in moderate-severe renal failure (risk of fatal hypermagnesemia). | Category B |
Security
Summary of Critical Interactions of the Vademecum
Three critical guidelines unify the clinical use of vitamins and minerals:
- Interference by Luminal Chelation: Divalent and trivalent cations (Ca2+, Mg2+, Fe2+, Zn2+) interact chemically in the digestive tract with drugs with a narrow therapeutic range, such as quinolones, tetracyclines and levothyroxine, forming insoluble chelates that block systemic absorption. Its administration should be spaced a minimum interval of 2 to 4 hours.
- Metabolism Disruption by Pharmacological Antagonists: Multiple commonly used drugs act as direct antagonists of vitamin pathways: isoniazid depletes vitamin B6; methotrexate irreversibly inhibits DHFR by blocking the activation of folic acid; and warfarin inactivates VKORC1, stopping the vitamin K cycle.
- Excretion Limits and Organ Toxicology: Fat-soluble vitamins (A, D, E) lack efficient rapid urinary clearance mechanisms, accumulating in fatty tissues and liver parenchyma, which favors the development of severe systemic toxicity due to overdose. On the contrary, the toxicity of water-soluble vitamins is mainly confined to chronic megadoses (neuropathy due to B6, renal oxalate lithiasis due to Vitamin C).
Clinical optimization using micronutrients requires a precise understanding of cellular transport mechanisms, interactions in the intestinal lumen and metabolic activation pathways.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Vitamins and Supplements
- Cluster
- Dosage Analysis and Safety Profiles